Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-individual comparison of Gd-EOB-DTPA disodium (Primovist) versus Gadovist in detection of hepatocellular carcinoma
2009-011095-30Phase 4Completed
- Sponsor
- Heidelberg University
- Start
- Jul 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of gadoxetate disodium in hepatocellular carcinoma (HCC), sponsored by Heidelberg University. Primary endpoint: Sensitivity for detection of HCC. Started Jul 2009; status: completed.
02
Drugs
gadoxetate disodium
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-011095-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011095-30.